Cogent Biosciences (COGT) Other Non-Current Assets (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Other Non-Current Assets of $1.9 million for Q1 2026, down 60.1% year-over-year from $4.9 million in Q1 2025, and up 366.35% quarter-over-quarter from $416000.0 in Q4 2025.
Cogent Biosciences (COGT) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Other Non-Current Assets for 10 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 60.1% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (down 60.1% YoY), while the FY2025 annual figure was $416000.0, down 91.44% from the prior year.
- Other Non-Current Assets grew to $1.9 million in Q1 2026 per COGT's latest filing, from $416000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $5.6 million in Q1 2022 and bottomed at $416000.0 in Q4 2025.
- Historically, Other Non-Current Assets has averaged $4.4 million across 5 years, with a median of $4.9 million in 2023.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 346.69% — and 2025, when it tumbled 91.44%.
- Cogent Biosciences' Other Non-Current Assets stood at $4.7 million in 2022, then rose by 2.51% to $4.9 million in 2023, then retreated by 0.04% to $4.9 million in 2024, then sank by 91.44% to $416000.0 in 2025, then soared by 366.35% to $1.9 million in 2026.
- Business Quant data shows COGT's Other Non-Current Assets at $1.9 million in Q1 2026, $416000.0 in Q4 2025, and $4.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | 1.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.94 Mn |
| Mar 31, 2026 | 1.94 Mn |
| Dec 31, 2025 | 416,000.00 |
| Sep 30, 2025 | 4.49 Mn |
| Jun 30, 2025 | 4.86 Mn |
| Mar 31, 2025 | 4.86 Mn |
| Dec 31, 2024 | 4.86 Mn |
| Sep 30, 2024 | 4.86 Mn |
| Jun 30, 2024 | 4.86 Mn |
| Mar 31, 2024 | 4.86 Mn |
| Dec 31, 2023 | 4.86 Mn |
| Sep 30, 2023 | 4.86 Mn |
| Jun 30, 2023 | 4.78 Mn |
| Mar 31, 2023 | 4.78 Mn |
| Dec 31, 2022 | 4.75 Mn |
| Sep 30, 2022 | 4.77 Mn |
| Jun 30, 2022 | 4.90 Mn |
| Mar 31, 2022 | 5.61 Mn |
| Dec 31, 2021 | 1.26 Mn |
| Sep 30, 2021 | 2.04 Mn |